GlassScriptPhysician profile
Sarah L Leo
NPI 1528564408
$2,233.70
in general payments reported to CMS, 2019-2025
15 companies · $803 in 2025
The $803 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $151 · 2023: $860 · 2024: $420 · 2025: $803.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,954 · Education: $128.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,953.99 |
| Education | $128.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $625.48 | 2022-2025 | Cuvitru, Takhzyro, Eohilia |
| Astrazeneca Pharmaceuticals LP | $543.91 | 2023-2025 | Tezspire, Fasenra, Airsupra |
| Genzyme Corporation | $273.00 | 2023-2024 | |
| Regeneron Healthcare Solutions, INC. | $214.51 | 2024-2025 | Dupixent |
| Genentech USA, INC. | $156.14 | 2025 | Xolair |
| Grifols USA, LLC | $116.75 | 2023-2025 | Xembify, Prolastin-C Liquid |
| Csl Behring | $76.44 | 2023-2024 | Hizentra |
| Pfizer INC. | $64.57 | 2025 | |
| Sanofi-Aventis U.S. LLC | $54.95 | 2023 | |
| Novartis Pharmaceuticals Corporation | $24.73 | 2025 | |
| Ars Pharmaceuticals Operations, INC. | $21.43 | 2025 | Neffy |
| Biocryst US Sales Co., LLC | $18.72 | 2024 | Orladeyo |
| Galderma Laboratories, L.P. | $15.43 | 2025 | Nemluvio |
| Glaxosmithkline, LLC. | $13.85 | 2025 | Shingrix |
| Lilly USA, LLC | $13.79 | 2025 | Ebglyss |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Leo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.